Edit

MannKind Corporation

http://mannkindcorp.com/

Last activity: 11.12.2024

Active

Categories: DevelopmentHealthTechHumanITLifeMedtechProduct

Drawing on the humanity and legacy of our founder, Alfred E. Mann, we’ve spent almost 3 decades developing cutting-edge therapeutic products and technologies to support our mission, to give people control over their health and the freedom to live life.

Likes

1.33K

Mentions

Location: United States, California, Westlake Village

Employees: 201-500

Phone: (818) 661-5000

Total raised: $160M

Founded date: 1991

Facebook

Instagram

Youtube

Investors 1

Date	Name	Website
-	Ignite 500	ignite500....

Funding Rounds 1

Date	Series	Amount	Investors
01.07.2013	-	$160M	-

Mentions in press and media 19

Date	Title	Description
11.12.2024	Cipla to bring in inhaled insulin Afrezza from US’ MannKind Corporation	Drugmaker Cipla has got regulatory approval to market Afrezza, a rapid acting insulin delivered through an inhaler, as compared to other insulins given through injections. The Central Drugs Standard Control Organisation (CDSCO) has given Ci...
02.04.2024	Jay Appel, Chief Innovation & Growth Officer at The Bloc, Inducted into DTC Perspectives' 2024 Hall of Fame for Transformative Impact in Healthcare Marketing	NEW YORK, April 2, 2024 /PRNewswire/ -- The Bloc, a renowned global health-native agency, is proud to announce that Jay Appel, Chief Innovation & Growth Officer, will be inducted into the DTC Hall of Fame for the year 2024. This is an h...
05.03.2024	MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8	-
09.11.2021	Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds	WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and o...
09.11.2021	Mannkind Corporation Closes Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds	WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Nov. 09, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and o...
29.09.2021	Mannkind Corporation Announces Sale-Leaseback Transaction Generating $102.25 Million in Non-Dilutive Gross Proceeds	WESTLAKE VILLAGE, Calif. and DANBURY, Conn., Sept. 29, 2021 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and ...
04.08.2021	NRx Pharmaceuticals : Partners with MannKind Corporation to Develop ZYESAMI™ (aviptadil) Inhaler for Respiratory Conditions	RADNOR, Pa., Aug. 4, 2021 /PRNewswire/ -- NRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with MannKind Corporation to develop a dry powder formulation of ZYESAMI™ (aviptadil), a synthetic form of human V...
28.06.2021	Policy Change Allows Approval For Medicare Patients Living With Diabetes To Use Both Afrezza® And Continuous Glucose Monitoring Devices Beginning July 18
03.06.2021	MannKind Announces Data Presentation At 14th International Conference On Advanced Technologies & Treatments For Diabetes (ATTD 2021) To Be Held Virtually June 2-5
13.05.2021	MannKind Announces Partnership With Type 1 Diabetes IndyCar Driver Conor Daly
30.12.2014	Maker of inhalable insulin marches on in wake of scrapped IPO	This isn’t the first time a company’s attempted an airborne diabetes med – yet there’s currently a hole in the market for such a product. Here’s why: A product called Exubera briefly hit the market around 2007 but was pulled by Pfizer barel...
13.08.2013	From inhalable insulin to vaccines: 5 diabetes companies to watch	Then there’s Pepex Biomedical, which is developing a line of all-in-one blood glucose meters that use biosensors and eliminate the need for testing strips. It’s also working on turning the technology into a cartridge that attaches to a smar...
01.07.2013	MannKind Gets $160M In Debt Funding	Valancia-based MannKind, which provides discovery, development, and commercialization of therapeutics products, said Monday that it has received $160M in a debt financing round. The publicly traded firm said the funding came from affiliates...
26.04.2012	Avandia to Alogliptin: A time line of recent FDA actions on diabetes drugs	July 2010: An FDA advisory panel holds a two-day meeting to discuss safety issues surrounding GSK’s Avandia, which in 2007 received a black box warning stating that the drug may cause heart attacks. The panel’s discussion divides the 33-mem...
12.10.2009	FDA to consider small inhaler for diabetes patients â€“ MedCity Morning Read, Oct. 12, 2009	Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev...
-	FDA to consider small inhaler for diabetes patients â€“ MedCity Morning Read, Oct. 12, 2009	Image via Wikipedia People with diabetes soon may be able to use a discreet device to inhale, rather than inject, insulin, according to The New York Times. The device, a small inhaler and insulin powder created by the Valencia, Calif.-based...
-	From inhalable insulin to vaccines: 5 diabetes companies to watch	With an estimated 370 million people expected to have diabetes by 2030, the already $41 million market for diabetes management products is set to skyrocket over the next several years. Fittingly, creating devices, drugs and services aimed a...
-	Avandia to Alogliptin: A time line of recent FDA actions on diabetes drugs	Diabetes drug alogliptin fell short of U.S. Food and Drug Administration approval on Wednesday, dealing a blow to the hopes of Takeda Pharmaceutical (TYO:4502) and its partner, Furiex Pharmaceuticals (NASDAQ:FURX). The complete response let...
-	Maker of inhalable insulin marches on in wake of scrapped IPO	It’s a drug meant for the injection-weary diabetic set: Dance Biopharm‘s developing an inhalable form of insulin, and a series accompanying electric devices to dispense the aerial hormone. It’s slated to go up against MannKind‘s Afrezza. Th...

MannKind Corporation

Investors 1

Funding Rounds 1

Mentions in press and media 19

Reviews 0